Vimian Group AB (publ) (VIMGF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vimian Group AB (publ) (VIMGF) trades at $2.77. Vimian Group AB (publ) operates in the animal health sector, offering a range of products and services across diagnostics, pharmaceuticals, MedTech, and veterinary services. Market cap: $1.46B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for VIMGF: VIMGF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VIMGF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on VIMGF.
How is this calculated? →Vimian Group AB (publ) (VIMGF) Healthcare & Pipeline Overview
Vimian Group AB operates in the global animal health market, providing specialized diagnostics, treatments, and services through its four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. Its focus on companion animals and livestock positions it within a growing sector driven by increased pet ownership and veterinary advancements.
What Is the Investment Thesis for VIMGF?
Vimian Group presents a compelling investment case due to its diversified business model within the growing animal health market. The company's focus on specialized diagnostics and treatments, particularly through its Nextmune and Indical Bioscience brands, positions it to capitalize on the increasing demand for advanced veterinary care. With a gross margin of 68.9% and a debt-to-equity ratio of 33.68%, Vimian demonstrates financial stability and growth potential. Key catalysts include the expansion of its VetFamily platform and the continued development of its MedTech offerings under the Movora brand. However, investors should be aware of the company's beta of 1.40, indicating higher volatility compared to the market.
Based on FMP financials and quantitative analysis
VIMGF Key Highlights
Market Cap of $1.46B reflects Vimian's significant presence in the animal health market.
- Gross Margin of 68.9% indicates strong pricing power and efficient operations.
- Profit Margin of 7.4% demonstrates profitability in a competitive industry.
- Debt-to-Equity Ratio of 33.68% suggests a balanced capital structure.
- Beta of 1.40 indicates higher volatility compared to the market.
Who Are VIMGF's Competitors?
VIMGF is benchmarked below against 3 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ZTS Zoetis Inc. | $75.44 | -1.62% | $31.6B | 85 |
| IDXX IDEXX Laboratories, Inc. | $545.86 | -2.91% | $43.1B | 92 |
| ERFSF Eurofins Scientific SE | $86.40 | +4.91% | $14.9B | 43 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VIMGF's Key Strengths?
Diversified business model across multiple segments of the animal health market.
- Proprietary diagnostics and treatments offer a competitive advantage.
- Strong brand reputation and customer loyalty.
- Experienced management team with a proven track record.
What Are VIMGF's Weaknesses?
High beta indicates higher volatility compared to the market.
- Dependence on veterinary channels for distribution.
- Limited geographic presence in certain markets.
- Relatively young company with a short operating history.
What Could Drive VIMGF Stock Higher?
Expansion of VetFamily platform into new geographic regions by Q4 2026.
- Continued development and launch of new diagnostic products by Indical Bioscience.
- Strategic partnerships with veterinary clinics and distributors to expand market reach.
What Are the Key Risks for VIMGF?
Intense competition from established players in the animal health market could impact market share.
- Regulatory changes and compliance requirements could increase operating costs.
- Economic downturns could affect pet ownership and veterinary spending, reducing demand for products and services.
- Dependence on veterinary channels for distribution exposes the company to channel-related risks.
- Fluctuations in currency exchange rates could impact financial performance.
What Are the Growth Opportunities for VIMGF?
- Expansion of VetFamily Platform: Vimian's VetFamily platform offers a significant growth opportunity by providing procurement, tech-driven operations, and community support to veterinary clinics. The platform's membership-based model generates recurring revenue and fosters customer loyalty. With the increasing adoption of digital solutions in veterinary practices, VetFamily is well-positioned to expand its market share and enhance its service offerings. The market for veterinary practice management software is projected to reach $500 million by 2028, providing a substantial runway for growth.
- Geographic Expansion of Nextmune: Nextmune's proprietary diagnostics and treatments for companion animals present a strong growth opportunity through geographic expansion. By entering new markets and establishing strategic partnerships with veterinary clinics and distributors, Nextmune can increase its global reach and revenue. The global market for companion animal healthcare is estimated at $30 billion, offering significant potential for Nextmune's expansion efforts.
- Development of Advanced Diagnostics: Vimian's Indical Bioscience is focused on developing advanced molecular and immunodiagnostic solutions for veterinary laboratories. The increasing demand for rapid and accurate diagnostics in both livestock and companion animal health markets drives the need for innovative diagnostic technologies.
- Innovation in Orthopedic Implants: Movora's orthopedic implants for veterinarians and universities represent a niche but growing market segment. By focusing on innovation and developing advanced implant technologies, Movora can differentiate itself from competitors and capture a larger share of the orthopedic market. The market for veterinary orthopedic implants is estimated at $200 million, offering opportunities for Movora to expand its product offerings and customer base.
- Strategic Acquisitions and Partnerships: Vimian Group can pursue strategic acquisitions and partnerships to expand its product portfolio, enter new markets, and enhance its technological capabilities. By acquiring complementary businesses and forming alliances with leading veterinary organizations, Vimian can accelerate its growth and strengthen its competitive position. The animal health market is characterized by consolidation, with larger companies acquiring smaller, innovative players to expand their offerings and market reach.
What Are VIMGF's Competitive Advantages?
- Proprietary diagnostics and treatments offer a competitive advantage.
- Membership-based VetFamily platform creates customer loyalty and recurring revenue.
- Strong brand reputation in the animal health market.
- Integrated business model across multiple segments provides diversification.
What Does VIMGF Do?
Vimian Group AB, established in 2020 and headquartered in Stockholm, Sweden, is a global animal health company committed to improving animal well-being through innovative products and services. The company operates through four distinct segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The Specialty Pharma segment, operating under the Nextmune brand, offers proprietary diagnostics, prescription, and non-prescription treatments focused on preventive care and chronic conditions in companion animals. The Diagnostics segment, branded as Indical Bioscience, provides molecular and immunodiagnostic solutions for veterinary laboratories, with a focus on both livestock and companion animal health markets. The MedTech segment, operating under the Movora brand, delivers orthopedic implants to veterinarians and universities. The Veterinary Services segment, branded as VetFamily, provides procurement, tech-driven operations, and a community platform for veterinary clinics, offering online marketing, education, and HR support through a membership-based model. Vimian's integrated approach across these segments allows it to address a wide range of animal health needs, from diagnostics and treatment to veterinary practice support.
What Products and Services Does VIMGF Offer?
- Develops and markets proprietary diagnostics for companion animals under the Nextmune brand.
- Offers prescription and non-prescription treatments for preventive care and chronic conditions in animals.
- Provides molecular and immunodiagnostic solutions for veterinary laboratories through Indical Bioscience.
- Supplies orthopedic implants for veterinarians and universities under the Movora brand.
- Operates VetFamily, a membership-based platform offering procurement, tech-driven operations, and community for veterinary clinics.
- Focuses on both companion animal and livestock health markets globally.
How Does VIMGF Make Money?
- Develops and sells proprietary diagnostics and treatments for animals.
- Provides a membership-based platform for veterinary clinics, generating recurring revenue.
- Sells orthopedic implants to veterinarians and universities.
- Generates revenue through its four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services.
What Industry Does VIMGF Operate In?
The animal health market is experiencing substantial growth, driven by increasing pet ownership, rising disposable incomes, and advancements in veterinary medicine. According to industry reports, the global animal health market is projected to reach $76 billion by 2027. Vimian Group operates in a competitive landscape that includes companies specializing in pharmaceuticals, diagnostics, and veterinary services. Key competitors include Zoetis and IDEXX Laboratories. Vimian differentiates itself through its integrated approach, offering a comprehensive suite of products and services across multiple segments of the animal health market.
Who Are VIMGF's Key Customers?
- Veterinary clinics and hospitals
- Veterinary diagnostic laboratories
- Universities and research institutions
- Pet owners (indirectly through veterinary channels)
Forward Outlook
Wall Street analysts project Vimian Group AB (publ) revenue of about $478.9M for fiscal 2026, with EPS near $0.10. The estimate reflects 5 contributing analysts.
VIMGF Valuation & Market Position
With a $1.46B market cap, Vimian Group AB (publ) sits in the small-cap segment of the market.
Key Financial Metrics
Return on equity for Vimian Group AB (publ) stands at 5.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.1%, showing how much profit it generates from its asset base. VIMGF trades at a trailing price-to-earnings ratio of 45.64, above the Healthcare sector average of ~23x. Its free cash flow yield is 4.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.43 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.2%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Vimian Group AB (publ)'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.64 places it in the grey zone, a middle ground that warrants monitoring.
Company Profile
Vimian Group AB (publ) operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Stockholm, SE. The company is led by CEO Alireza Tajbakhsh. VIMGF has traded publicly since 2022.
VIMGF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Vimian's insider buying suggests strong confidence from those who know the company best.
- The pet care market is generally seen as recession-resistant, offering a stable demand base.
- Community sentiment indicates optimism about Vimian's growth strategy in specialized veterinary services.
- Market perception views Vimian as strategically positioned to consolidate a fragmented industry, similar to how Idexx built its dominance.
Bear Case
- Recent market volatility could impact Vimian's growth trajectory, mirroring challenges faced by other growth stocks.
- Community discussions highlight concerns about integration risks from Vimian's acquisition strategy.
- Bearish voices in the community question the sustainability of Vimian's premium valuation in a competitive landscape.
- Increased competition in the specialized veterinary market may erode Vimian's profit margins, akin to pressures seen in other niche healthcare sectors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VIMGF Latest News
No recent news available for VIMGF.
VIMGF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VIMGF.
Price Targets
Wall Street price target analysis for VIMGF.
VIMGF MoonshotScore
What does this score mean?
The MoonshotScore rates VIMGF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
VIMGF OTC Market Information
VIMGF trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
Vimian Group AB (publ) Healthcare Stock: Key Questions Answered
What does Vimian Group AB (publ) do?
Vimian Group AB (publ) operates in the animal health sector, focusing on diagnostics, pharmaceuticals, MedTech, and veterinary services. The company develops and markets proprietary diagnostics and treatments for companion animals through its Nextmune brand. It also provides molecular and immunodiagnostic solutions for veterinary laboratories via Indical Bioscience.
What are the main risks for VIMGF?
Vimian Group faces several risks inherent to the animal health industry. Intense competition from established players like Zoetis and IDEXX Laboratories could impact market share and pricing power. Regulatory changes and compliance requirements in different geographic markets could increase operating costs and delay product approvals.
What are the key factors to evaluate for VIMGF?
Evaluate VIMGF on fundamentals, analyst consensus, and risk factors. Vimian Group presents a compelling investment case due to its diversified business model within the growing animal health market. Not financial advice.
How frequently does VIMGF data refresh on this page?
VIMGF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VIMGF's recent stock price performance?
Vimian Group AB (publ) (VIMGF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified business model across multiple segments of the animal health market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VIMGF overvalued or undervalued right now?
Vimian Group AB (publ) (VIMGF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VIMGF before investing?
Before investing in Vimian Group AB (publ) (VIMGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding VIMGF to a portfolio?
Key strength of Vimian Group AB (publ) (VIMGF): Diversified business model across multiple segments of the animal health market. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.